Literature DB >> 29524111

Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil.

Renato D Lopes1, Patricia O Guimarães2, Mark Crowther3, Elaine Hylek4, Gilson S Feitosa-Filho5,6,7, Luiz E Ritt5,8, Nivaldo Filgueiras9,10,11,12, David A Garcia13.   

Abstract

To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Tenth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, on September 22 and 23, 2017. This scientific program was developed by clinicians for clinicians and was promoted by two major clinical research institutes-the Brazilian Clinical Research Institute and the Duke Clinical Research Institute of the Duke University School of Medicine. Comprising academic presentations and open discussion, the symposium had as its primary goal to educate, motivate, and inspire internists, cardiologists, hematologists, and other physicians by convening national and international visionaries, thought-leaders, and dedicated clinician-scientists. This paper summarizes the symposium proceedings.

Entities:  

Keywords:  Antithrombotic therapy; Clinical research; Guidelines; Thrombosis

Mesh：

Substances：

Year:  2018        PMID： 29524111     DOI： 10.1007/s11239-018-1639-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  30 in total

1.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

3.  Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.

Authors:  C W Francis; C M Kessler; S Z Goldhaber; M J Kovacs; M Monreal; M V Huisman; D Bergqvist; A G Turpie; T L Ortel; A C Spyropoulos; I Pabinger; A K Kakkar
Journal:  J Thromb Haemost       Date:  2015-05-10       Impact factor: 5.824

4.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Authors:  John W Eikelboom; Stuart J Connolly; Jackie Bosch; Gilles R Dagenais; Robert G Hart; Olga Shestakovska; Rafael Diaz; Marco Alings; Eva M Lonn; Sonia S Anand; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Kelley R H Branch; Jeffrey Probstfield; Deepak L Bhatt; Jun Zhu; Yan Liang; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Ajay K Kakkar; Keith A A Fox; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Matyas Keltai; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; P Gabriel Steg; Kaj P Metsarinne; Nancy Cook Bruns; Frank Misselwitz; Edmond Chen; Darryl Leong; Salim Yusuf
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning.

Authors:  C O'Connell; P Razavi; M Ghalichi; S Boyle; S Vasan; L Mark; A Caton; V Duddalwar; W Boswell; K Grabow; H A Liebman
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

Review 6.  Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates.

Authors:  Deborah Siegal; Jovana Yudin; Scott Kaatz; James D Douketis; Wendy Lim; Alex C Spyropoulos
Journal:  Circulation       Date:  2012-08-21       Impact factor: 29.690

7.  Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.

Authors:  William L Baker; Deborah A Cios; Stephen D Sander; Craig I Coleman
Journal:  J Manag Care Pharm       Date:  2009-04

8.  Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region.

Authors:  Tomas Forslund; Björn Wettermark; Per Wändell; Mia von Euler; Jan Hasselström; Paul Hjemdahl
Journal:  Eur J Clin Pharmacol       Date:  2014-09-16       Impact factor: 2.953

9.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

Review 10.  Guidance for the prevention and treatment of cancer-associated venous thromboembolism.

Authors:  Alok A Khorana; Marc Carrier; David A Garcia; Agnes Y Y Lee
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.